This activity of the anti–MMP-9 antibody could also be contributing to the increased immune signatures in tumors, and is of notable translational relevance given that CXCR3 ligands in the tumor microenvironment are associated with response to adoptive transfer and checkpoint therapies[23–26, 38]. Here, CXCR3 is linked to neoplasm.